首页 校区介绍 组织机构 书院风采 学院设置 师资队伍 招生就业 人才培养 科学研究 国际交流 采购招标 校友-捐赠  

【学术报告】题目:Development of basic tools for glycoscience and their application to translational research


题目:Development of basic tools for glycoscience and their application to translational research' 

报告人:成松久教授

报告时间:2018426 1330

报告地点:F03-201

报告人简介:Dr. Narimatsu is founder and Director of the Research Center of Medical Glycoscience (RCMG), a part of National Institute of Advanced Industrial Science and Technology (AIST) in Japan. He graduated from the School of Medicine and Graduate School of Medicine at Keio University where he received his MD and PhD respectively. During his postdoctoral studies at U.S. National Institutes of Health (NIH), he successfully cloned the first glycosyltransferase, beta1,4galactosyltransferase and thereafter, has continuously devoted his scientific career to finding and cloning many new glycosyltransferases. In 2000 he joined AIST and has since lead 3 national projects to facilitate the progress of glycoscience: the Glycogene Project, the Structural Glycomics Project, and the Medical Glycomics Project.

 

报告摘要:We have been developing many basic technologies which are required for glycoscience for these 17 years.  Firstly, we discovered many glycogenes which are responsible for glycerin synthesis. We can now synthesize a variety of glycan structures using such recombinant enzymes. For structural analysis of glycans, we have mainly developed two technologies, 1) MS based analysis of glycans and glycopeptides, and 2) lectin microarray that is the most sensitive array for glycan profiling.  These many technologies were applied to the medical issues,  particularly, to develop diagnostics.  We have been successful in completing the assay kit for the diagnosis of liver fibrosis. This diagnosis kit named M2BPGi is now world-widely used for the diagnosis of chronic hepatitis and liver cirrhosis. The validation studies on M2BPGi verified its clinical importance for the level of liver fibrosis, and over 50 scientific clinical papers describing M2BPGi were already reported to date. The second success named MUC1Gi is the diagnostics for cholangiocarcinoma. Thus, we are now developing clinically useful diagnostics for several diseases.



(来源:生命与医药学院、科研与学科工作部  作者:生命与医药学院  编辑:科研与学科工作部  更新:2018-04-25  点击:次)
 
 校区信息公开  
 
         校区文件             校务公开
 公告  
 工作简报  
校区简报第五十期 2018-04-12
校区简报第四十九期 2018-03-23
 我爱校区  
 高教动态  
教育部办公厅印发通知实施高校思...
辽宁向高校放“引才”权
教育部办公厅关于2017年教育部政...
 新媒体  
大连理工大学盘锦校区新浪微博 大连理工大学盘锦校区QQ空间 大连理工大学盘锦校区人人网公共主页 大连理工大学盘锦校区微信公众平台
    地址:辽宁省盘锦市辽东湾新区大工路2号     邮编:124221     电话/传真:0427-2631111       0427-2631928
       辽宁省大连市甘井子区凌工路2号大连理工大学主楼西侧楼227房间 邮编:116024
 
大连理工大学盘锦校区 版权所有  Copyright ? 2013 All rights reserved.  辽ICP备05001357号